Fibrosis, regeneration and cancer: what is the link?

Tubulo-interstitial fibrosis constitutes the final common pathway for all pathological conditions that evolve towards chronic kidney disease, and transforming growth factor-β1 plays a key role in this process. Furthermore, neutrophil gelatinase-associated lipocalin appears not only to be a simple ma...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Nephrology, dialysis, transplantation dialysis, transplantation, 2012-01, Vol.27 (1), p.21-27
Hauptverfasser: CERNARO, Valeria, LACQUANITI, Antonio, DONATO, Valentina, ROSARIA FAZIO, Maria, BUEMI, Antoine, BUEMI, Michele
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 27
container_issue 1
container_start_page 21
container_title Nephrology, dialysis, transplantation
container_volume 27
creator CERNARO, Valeria
LACQUANITI, Antonio
DONATO, Valentina
ROSARIA FAZIO, Maria
BUEMI, Antoine
BUEMI, Michele
description Tubulo-interstitial fibrosis constitutes the final common pathway for all pathological conditions that evolve towards chronic kidney disease, and transforming growth factor-β1 plays a key role in this process. Furthermore, neutrophil gelatinase-associated lipocalin appears not only to be a simple marker of renal injury but also an active player in disease progression. We are not yet able to control and modulate this phenomenon. Therefore, a better understanding of fibrogenic molecular mechanisms is necessary to detect possible therapeutic strategies that interfere with fibrosis and then stop the progression of renal disease. The line of research called 'regenerative medicine' works toward this. According to many authors, the formation of a fibrotic extracellular matrix disrupts the cells' polarity and stimulates their proliferation, creating conditions for cancer development. However, there is another plausible hypothesis: is it possible that fibrosis provides a sort of 'protection' from the development of a cancer as a consequence of the intense proliferation that characterizes any inflammatory process? In superior organisms, and also in humans, regeneration may have been selected negatively and replaced by fibrosis in the course of evolution, to warrant species survival: in fact, unchecked pluripotent cell production and proliferation can lead to tumour development and the potential death of a single individual. Hence, tumours might be the outcome of the failure of fibrotic processes, most likely due to some mediators predominating over others. So, valid experimental models are necessary to understand the interactions that exist between fibrosis and tumours and to evaluate the real advantage of therapies that aim to inhibit the fibrotic process at the renal level or that of other organs. The ideal approach would be to limit fibrosis and then organ function loss but without exposing the patient to risks of developing a tumour, starting from as early as the drugs prescribed.
doi_str_mv 10.1093/ndt/gfr567
format Article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_918935361</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>918935361</sourcerecordid><originalsourceid>FETCH-LOGICAL-c418t-343aaa6799404faf0d79178254c9d0468cbd4acd007ce4b5a5a8304e7a3d47c23</originalsourceid><addsrcrecordid>eNpF0EFLwzAUwPEgipvTix9AehFBrHtpkqbxIjKcCgMveg6vSbpFu3YmLeK3t7Kpp3d4Px68PyGnFK4pKDZtbDddVkHkco-MKc8hzVgh9sl4WNIUBKgROYrxDQBUJuUhGWUZhSyn-ZjwuS9DG328SoJbusYF7HzbJNjYxGBjXLhJPlfYJT4m3coltW_eb4_JQYV1dCe7OSGv8_uX2WO6eH54mt0tUsNp0aWMM0TMpVIceIUVWKmoLDLBjbLA88KUlqOxANI4XgoUWDDgTiKzXJqMTcjF9u4mtB-9i51e-2hcXWPj2j5qRQvFBMvpIC-30gzPxOAqvQl-jeFLU9A_kfQQSW8jDfhsd7Yv187-0d8qAzjfAYwG6yoMIXz8d0JIKiVn37XAboE</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>918935361</pqid></control><display><type>article</type><title>Fibrosis, regeneration and cancer: what is the link?</title><source>Oxford University Press Journals All Titles (1996-Current)</source><source>MEDLINE</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>Alma/SFX Local Collection</source><creator>CERNARO, Valeria ; LACQUANITI, Antonio ; DONATO, Valentina ; ROSARIA FAZIO, Maria ; BUEMI, Antoine ; BUEMI, Michele</creator><creatorcontrib>CERNARO, Valeria ; LACQUANITI, Antonio ; DONATO, Valentina ; ROSARIA FAZIO, Maria ; BUEMI, Antoine ; BUEMI, Michele</creatorcontrib><description>Tubulo-interstitial fibrosis constitutes the final common pathway for all pathological conditions that evolve towards chronic kidney disease, and transforming growth factor-β1 plays a key role in this process. Furthermore, neutrophil gelatinase-associated lipocalin appears not only to be a simple marker of renal injury but also an active player in disease progression. We are not yet able to control and modulate this phenomenon. Therefore, a better understanding of fibrogenic molecular mechanisms is necessary to detect possible therapeutic strategies that interfere with fibrosis and then stop the progression of renal disease. The line of research called 'regenerative medicine' works toward this. According to many authors, the formation of a fibrotic extracellular matrix disrupts the cells' polarity and stimulates their proliferation, creating conditions for cancer development. However, there is another plausible hypothesis: is it possible that fibrosis provides a sort of 'protection' from the development of a cancer as a consequence of the intense proliferation that characterizes any inflammatory process? In superior organisms, and also in humans, regeneration may have been selected negatively and replaced by fibrosis in the course of evolution, to warrant species survival: in fact, unchecked pluripotent cell production and proliferation can lead to tumour development and the potential death of a single individual. Hence, tumours might be the outcome of the failure of fibrotic processes, most likely due to some mediators predominating over others. So, valid experimental models are necessary to understand the interactions that exist between fibrosis and tumours and to evaluate the real advantage of therapies that aim to inhibit the fibrotic process at the renal level or that of other organs. The ideal approach would be to limit fibrosis and then organ function loss but without exposing the patient to risks of developing a tumour, starting from as early as the drugs prescribed.</description><identifier>ISSN: 0931-0509</identifier><identifier>EISSN: 1460-2385</identifier><identifier>DOI: 10.1093/ndt/gfr567</identifier><identifier>PMID: 22102616</identifier><identifier>CODEN: NDTREA</identifier><language>eng</language><publisher>Oxford: Oxford University Press</publisher><subject>Anesthesia. Intensive care medicine. Transfusions. Cell therapy and gene therapy ; Animals ; Biological and medical sciences ; Disease Progression ; Emergency and intensive care: renal failure. Dialysis management ; Fibrosis - pathology ; Humans ; Intensive care medicine ; Kidney Diseases - etiology ; Kidney Diseases - pathology ; Medical sciences ; Neoplasms - etiology ; Neoplasms - pathology ; Nephrology. Urinary tract diseases ; Nephropathies. Renovascular diseases. Renal failure ; Regeneration ; Tubulopathies</subject><ispartof>Nephrology, dialysis, transplantation, 2012-01, Vol.27 (1), p.21-27</ispartof><rights>2015 INIST-CNRS</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c418t-343aaa6799404faf0d79178254c9d0468cbd4acd007ce4b5a5a8304e7a3d47c23</citedby><cites>FETCH-LOGICAL-c418t-343aaa6799404faf0d79178254c9d0468cbd4acd007ce4b5a5a8304e7a3d47c23</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,27901,27902</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&amp;idt=25571774$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/22102616$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>CERNARO, Valeria</creatorcontrib><creatorcontrib>LACQUANITI, Antonio</creatorcontrib><creatorcontrib>DONATO, Valentina</creatorcontrib><creatorcontrib>ROSARIA FAZIO, Maria</creatorcontrib><creatorcontrib>BUEMI, Antoine</creatorcontrib><creatorcontrib>BUEMI, Michele</creatorcontrib><title>Fibrosis, regeneration and cancer: what is the link?</title><title>Nephrology, dialysis, transplantation</title><addtitle>Nephrol Dial Transplant</addtitle><description>Tubulo-interstitial fibrosis constitutes the final common pathway for all pathological conditions that evolve towards chronic kidney disease, and transforming growth factor-β1 plays a key role in this process. Furthermore, neutrophil gelatinase-associated lipocalin appears not only to be a simple marker of renal injury but also an active player in disease progression. We are not yet able to control and modulate this phenomenon. Therefore, a better understanding of fibrogenic molecular mechanisms is necessary to detect possible therapeutic strategies that interfere with fibrosis and then stop the progression of renal disease. The line of research called 'regenerative medicine' works toward this. According to many authors, the formation of a fibrotic extracellular matrix disrupts the cells' polarity and stimulates their proliferation, creating conditions for cancer development. However, there is another plausible hypothesis: is it possible that fibrosis provides a sort of 'protection' from the development of a cancer as a consequence of the intense proliferation that characterizes any inflammatory process? In superior organisms, and also in humans, regeneration may have been selected negatively and replaced by fibrosis in the course of evolution, to warrant species survival: in fact, unchecked pluripotent cell production and proliferation can lead to tumour development and the potential death of a single individual. Hence, tumours might be the outcome of the failure of fibrotic processes, most likely due to some mediators predominating over others. So, valid experimental models are necessary to understand the interactions that exist between fibrosis and tumours and to evaluate the real advantage of therapies that aim to inhibit the fibrotic process at the renal level or that of other organs. The ideal approach would be to limit fibrosis and then organ function loss but without exposing the patient to risks of developing a tumour, starting from as early as the drugs prescribed.</description><subject>Anesthesia. Intensive care medicine. Transfusions. Cell therapy and gene therapy</subject><subject>Animals</subject><subject>Biological and medical sciences</subject><subject>Disease Progression</subject><subject>Emergency and intensive care: renal failure. Dialysis management</subject><subject>Fibrosis - pathology</subject><subject>Humans</subject><subject>Intensive care medicine</subject><subject>Kidney Diseases - etiology</subject><subject>Kidney Diseases - pathology</subject><subject>Medical sciences</subject><subject>Neoplasms - etiology</subject><subject>Neoplasms - pathology</subject><subject>Nephrology. Urinary tract diseases</subject><subject>Nephropathies. Renovascular diseases. Renal failure</subject><subject>Regeneration</subject><subject>Tubulopathies</subject><issn>0931-0509</issn><issn>1460-2385</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2012</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNpF0EFLwzAUwPEgipvTix9AehFBrHtpkqbxIjKcCgMveg6vSbpFu3YmLeK3t7Kpp3d4Px68PyGnFK4pKDZtbDddVkHkco-MKc8hzVgh9sl4WNIUBKgROYrxDQBUJuUhGWUZhSyn-ZjwuS9DG328SoJbusYF7HzbJNjYxGBjXLhJPlfYJT4m3coltW_eb4_JQYV1dCe7OSGv8_uX2WO6eH54mt0tUsNp0aWMM0TMpVIceIUVWKmoLDLBjbLA88KUlqOxANI4XgoUWDDgTiKzXJqMTcjF9u4mtB-9i51e-2hcXWPj2j5qRQvFBMvpIC-30gzPxOAqvQl-jeFLU9A_kfQQSW8jDfhsd7Yv187-0d8qAzjfAYwG6yoMIXz8d0JIKiVn37XAboE</recordid><startdate>20120101</startdate><enddate>20120101</enddate><creator>CERNARO, Valeria</creator><creator>LACQUANITI, Antonio</creator><creator>DONATO, Valentina</creator><creator>ROSARIA FAZIO, Maria</creator><creator>BUEMI, Antoine</creator><creator>BUEMI, Michele</creator><general>Oxford University Press</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>20120101</creationdate><title>Fibrosis, regeneration and cancer: what is the link?</title><author>CERNARO, Valeria ; LACQUANITI, Antonio ; DONATO, Valentina ; ROSARIA FAZIO, Maria ; BUEMI, Antoine ; BUEMI, Michele</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c418t-343aaa6799404faf0d79178254c9d0468cbd4acd007ce4b5a5a8304e7a3d47c23</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2012</creationdate><topic>Anesthesia. Intensive care medicine. Transfusions. Cell therapy and gene therapy</topic><topic>Animals</topic><topic>Biological and medical sciences</topic><topic>Disease Progression</topic><topic>Emergency and intensive care: renal failure. Dialysis management</topic><topic>Fibrosis - pathology</topic><topic>Humans</topic><topic>Intensive care medicine</topic><topic>Kidney Diseases - etiology</topic><topic>Kidney Diseases - pathology</topic><topic>Medical sciences</topic><topic>Neoplasms - etiology</topic><topic>Neoplasms - pathology</topic><topic>Nephrology. Urinary tract diseases</topic><topic>Nephropathies. Renovascular diseases. Renal failure</topic><topic>Regeneration</topic><topic>Tubulopathies</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>CERNARO, Valeria</creatorcontrib><creatorcontrib>LACQUANITI, Antonio</creatorcontrib><creatorcontrib>DONATO, Valentina</creatorcontrib><creatorcontrib>ROSARIA FAZIO, Maria</creatorcontrib><creatorcontrib>BUEMI, Antoine</creatorcontrib><creatorcontrib>BUEMI, Michele</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Nephrology, dialysis, transplantation</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>CERNARO, Valeria</au><au>LACQUANITI, Antonio</au><au>DONATO, Valentina</au><au>ROSARIA FAZIO, Maria</au><au>BUEMI, Antoine</au><au>BUEMI, Michele</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Fibrosis, regeneration and cancer: what is the link?</atitle><jtitle>Nephrology, dialysis, transplantation</jtitle><addtitle>Nephrol Dial Transplant</addtitle><date>2012-01-01</date><risdate>2012</risdate><volume>27</volume><issue>1</issue><spage>21</spage><epage>27</epage><pages>21-27</pages><issn>0931-0509</issn><eissn>1460-2385</eissn><coden>NDTREA</coden><abstract>Tubulo-interstitial fibrosis constitutes the final common pathway for all pathological conditions that evolve towards chronic kidney disease, and transforming growth factor-β1 plays a key role in this process. Furthermore, neutrophil gelatinase-associated lipocalin appears not only to be a simple marker of renal injury but also an active player in disease progression. We are not yet able to control and modulate this phenomenon. Therefore, a better understanding of fibrogenic molecular mechanisms is necessary to detect possible therapeutic strategies that interfere with fibrosis and then stop the progression of renal disease. The line of research called 'regenerative medicine' works toward this. According to many authors, the formation of a fibrotic extracellular matrix disrupts the cells' polarity and stimulates their proliferation, creating conditions for cancer development. However, there is another plausible hypothesis: is it possible that fibrosis provides a sort of 'protection' from the development of a cancer as a consequence of the intense proliferation that characterizes any inflammatory process? In superior organisms, and also in humans, regeneration may have been selected negatively and replaced by fibrosis in the course of evolution, to warrant species survival: in fact, unchecked pluripotent cell production and proliferation can lead to tumour development and the potential death of a single individual. Hence, tumours might be the outcome of the failure of fibrotic processes, most likely due to some mediators predominating over others. So, valid experimental models are necessary to understand the interactions that exist between fibrosis and tumours and to evaluate the real advantage of therapies that aim to inhibit the fibrotic process at the renal level or that of other organs. The ideal approach would be to limit fibrosis and then organ function loss but without exposing the patient to risks of developing a tumour, starting from as early as the drugs prescribed.</abstract><cop>Oxford</cop><pub>Oxford University Press</pub><pmid>22102616</pmid><doi>10.1093/ndt/gfr567</doi><tpages>7</tpages><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 0931-0509
ispartof Nephrology, dialysis, transplantation, 2012-01, Vol.27 (1), p.21-27
issn 0931-0509
1460-2385
language eng
recordid cdi_proquest_miscellaneous_918935361
source Oxford University Press Journals All Titles (1996-Current); MEDLINE; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; Alma/SFX Local Collection
subjects Anesthesia. Intensive care medicine. Transfusions. Cell therapy and gene therapy
Animals
Biological and medical sciences
Disease Progression
Emergency and intensive care: renal failure. Dialysis management
Fibrosis - pathology
Humans
Intensive care medicine
Kidney Diseases - etiology
Kidney Diseases - pathology
Medical sciences
Neoplasms - etiology
Neoplasms - pathology
Nephrology. Urinary tract diseases
Nephropathies. Renovascular diseases. Renal failure
Regeneration
Tubulopathies
title Fibrosis, regeneration and cancer: what is the link?
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-02T21%3A24%3A40IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Fibrosis,%20regeneration%20and%20cancer:%20what%20is%20the%20link?&rft.jtitle=Nephrology,%20dialysis,%20transplantation&rft.au=CERNARO,%20Valeria&rft.date=2012-01-01&rft.volume=27&rft.issue=1&rft.spage=21&rft.epage=27&rft.pages=21-27&rft.issn=0931-0509&rft.eissn=1460-2385&rft.coden=NDTREA&rft_id=info:doi/10.1093/ndt/gfr567&rft_dat=%3Cproquest_cross%3E918935361%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=918935361&rft_id=info:pmid/22102616&rfr_iscdi=true